-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Raises Price Target to $40

Benzinga·11/13/2026 12:40:02
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and raises the price target from $36 to $40.